Caris Life Sciences (CAI) Cost of Revenue (2024 - 2026)

Caris Life Sciences' Cost of Revenue history runs 3 years deep, the most recent figure standing at $45.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 13.09% year-over-year to $45.0 million; the TTM figure through Mar 2026 stood at $172.7 million (up 13.02% YoY), while the FY2025 annual figure was $167.5 million, up 9.77% from the prior year.
• Cost of Revenue was $45.0 million for Q1 2026 at Caris Life Sciences, up from $44.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $45.0 million in Q1 2026 to a low of $36.8 million in Q3 2024.
• Historically, Cost of Revenue has averaged $40.7 million across 3 years, with a median of $40.5 million in 2025.
• Biggest YoY gain for Cost of Revenue was 17.66% in 2025; the steepest drop was 9.17% in 2025.
• A 3-year view of Cost of Revenue shows it stood at $37.5 million in 2024, then increased by 17.66% to $44.2 million in 2025, then advanced by 2.02% to $45.0 million in 2026.
• The last three Cost of Revenue figures came in at $45.0 million (Q1 2026), $44.2 million (Q4 2025), and $41.3 million (Q3 2025), per Business Quant data.